Mcboben

Company Description

Formed in 2011, McBoben Health Science is the first in a new generation of health-science companies. Advancing the role of nutritional and fruits therapy to change the course of health management for consumers, we believe natural ingredients are more effective than chemicals. Our focus is on feeling oneness with patients and partners. Investing in novelty and leveraging leading-edge science, we are forging a new industry between food and chemical pharmaceuticals. Initially founded on Nano Nutrition Research, our approach is based on: inherently safe nutritional therapies; relevant levels of quality of spiritual life benefits; and proven clinical and health economic value which will be attained till 2025. Our global mindset has led us to expand throughout both Europe and Asia, with our headquarters located in Sydney, Australia. We have established a portfolio of consumer and medical nutrition brands, and utilise our extensive molecular knowledge to address the specific needs of over ten million people daily, and much more annually. We are energetically involved in identifying fundamental scientific Ultra-advances and making them accessible to consumers worldwide by building a transformational pipeline. We understand how naturally occurring nutrients can be used to impact disease at a cellular level, along with their potentially greater therapeutic benefit to the health of the human body. To date, our activities include a number of acquisitions and investments: PCNS – a portfolio of clinical nutritional solutions for understanding how the deficiency of natural vitamins and minerals affecting our ageing which epidemically is happening of limiting the time for planning our food according to our vitamin and mineral needs (especially for young population errors of ageing related to their biological ageing); Golden Flower Laboratory – diagnostics and Biopharmaceuticals in gastroenterology (GI) and oncology; RadianHealth – prescription medical foods for the brain and metabolic disorders; Nutrition Science Partners (joint venture) – exploring the potential of botanical-based nutrients, focusing on gastrointestinal disorders; and Makin (minority stake) – supporting trials of nutritional therapy for people suffering from Alzheimer’s disease